Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Hereditary hemochromatosis type 4 is an autosomal-dominant inherited disease characterized by a mutation in the SLC40A1 gene encoding ferroportin. This condition can be further subdivided into types 4A (loss-of-function mutations) and 4B (gain-of-function mutations). To date, only a few cases of type 4B cases have been reported, and the treatment has not been clearly mentioned. Here, we report a genotype of hereditary hemochromatosis type 4B involving the heterozygous mutation c.997 T > C (p. Tyr333His) in SLC40A1. The patient was treated with red blood cell apheresis every month for 1 year, followed by oral deferasirox, and the combined therapy was found to be effective.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00795-023-00359-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hemochromatosis Proteins Hemojuvelin and Homeostatic Iron Regulator in Bone Morphogenetic Protein-Mediated Hepcidin Regulation and Iron Homeostasis.
Am J Hematol
September 2025
Nephrology Division and Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
The bone morphogenetic protein (BMP)-SMAD signaling pathway is central to regulating hepcidin, the master regulator of systemic iron homeostasis. We have previously demonstrated that BMP6, BMP2, and, to a lesser extent, BMP5 are the major ligands contributing to hepcidin and iron homeostasis regulation in vivo. Hemojuvelin (HJV) and homeostatic iron regulator (HFE) are hepcidin modulators that are mutated in hereditary hemochromatosis.
View Article and Find Full Text PDFHemochromatosis: A Risk Factor for Breast Cancer? Systematic Review and Meta-Analysis.
Eur J Breast Health
September 2025
Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France.
Objective: Hereditary hemochromatosis and breast cancer are two major public health problems. The gene variants C282Y and H63D, responsible for most cases of hemochromatosis, may contribute to carcinogenesis via iron overload, oxidative stress, and hormonal modulation. The aim of this study was to evaluate the association between variants and breast cancer risk and propose a personalized surveillance strategy.
View Article and Find Full Text PDFBeyond the iron gate: Therapeutic donation at Lifeblood for patients with haemochromatosis.
Aust J Gen Pract
September 2025
BSc (Hons), MSocHlth, PhD, Senior Research Fellow, Research and Development, Australian Red Cross Lifeblood, Melbourne, Vic; Honorary Senior Fellow, Melbourne School of Population and Global Health, The University of Melbourne, Vic.
Background And Objectives: Australian Red Cross Lifeblood (Lifeblood) provides therapeutic venesection for patients who meet evidence-based eligibility criteria. Many of these patients have iron overload due to hereditary haemochromatosis (HHC). This study aimed to gain knowledge into the demographic characteristics of donors with haemochromatosis and to investigate their knowledge, compliance and experiences with their condition.
View Article and Find Full Text PDFA Case of Turmeric-Induced Hepatotoxicity with Hyperferritinemia.
Case Rep Gastroenterol
March 2025
Lankenau Medical Center and Lankenau Institute for Medical Research, Penn Wynne, PA, USA.
Introduction: We present the first published case of turmeric-associated drug-induced liver injury (DILI) accompanied by significant ferritin elevation.
Case Presentation: Our patient, a 59-year-old female with DILI caused by long-term ingestion of oral turmeric supplements, presented with painless jaundice on an annual exam. The patient's liver function tests exhibited a hepatocellular pattern and hyperferritinemia (>2,000 ng/dL).
Old Therapy, New Questions: Rethinking Phlebotomy in a Pharmacologic Landscape.
Pharmaceuticals (Basel)
August 2025
Hematology and Bone Marrow Transplantation Unit (BMTU), Hospital of Bolzano (SABES-ASDAA), Teaching Hospital of Paracelsus Medical University (PMU), 39100 Bolzano, Italy.
Therapeutic phlebotomy remains a key intervention in the management of erythrocytosis and iron overload disorders, particularly polycythemia vera (PV) and hereditary hemochromatosis. Despite its historical origins as an ancient practice, venesection continues to be recommended in international guidelines for the reduction of hematocrit and iron burden, thereby mitigating thrombotic and organ-related complications. However, the evolving landscape of targeted pharmacologic therapies is reshaping the therapeutic paradigm.
View Article and Find Full Text PDF